Author(s):
Sonam Sharma, Nisha Sharma, Prakash Chandra Gupta, Ruchi Verma, Vandana Yadav
Email(s):
drxsonamsharma@gamil.com
DOI:
10.52711/0975-4385.2023.00009 
Address:
Sonam Sharma1*, Nisha Sharma2, Prakash Chandra Gupta2, Ruchi Verma3, Vandana Yadav3
1Research Scholar, School of Pharmaceutical Sciences, Chhatrapati Sahu Ji Maharaj University, Kanpur, Uttar Pradesh, India.
2Associate Professor, School of Pharmaceutical Sciences, Chhatrapati Sahu Ji Maharaj University, Kanpur, Uttar Pradesh, India.
3Research Scholar, School of Pharmaceutical Sciences, Chhatrapati Sahu Ji Maharaj University, Kanpur, Uttar Pradesh, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 1,
Year - 2023
ABSTRACT:
Kidney stone illness is becoming more common and new studies shows that stones can be linked to a number of significant complications. Renal stone disorder is a condition of crystal concretion that forms in the kidney. It is a growing urological health problem that affects approximately 12% of the global population. Stone generation is a sophisticated process that includes a number of physicochemical phenomena, such as supersaturation of urine, nucleation, growth of crystal, crystal aggregation and retention of urinary stone. An imbalance between substances that induce or inhibit urine crystallisation controls these stages. These facts show stone therapy and stone prevention. There is many misunderstanding regarding how to handle stones among both the general public and clinicians. As a result, review is to consolidate up-to-date knowledge on kidney stone origin, pathophysiology, and management strategies of each kind of kidney stone. The phytochemicals present in the extract contribute to the plant's antiurolithiatic abilities. Several kinds of phytochemicals such as Flavonoids, Polysaccharide, Saponin etc have a favourable effect in the antiurolithiatic impact against kidney crystals, or in terms of dissolving or inhibitory capabilities. However, there is a limited knowledge on nutritional and medicinal treatments for lithiasis and prevention.
Cite this article:
Sonam Sharma, Nisha Sharma, Prakash Chandra Gupta, Ruchi Verma, Vandana Yadav. An Update on Kidney Stones: Types, Mechanism and Treatment Approaches. Research Journal of Pharmacognosy and Phytochemistry. 2023; 15(1):53-2. doi: 10.52711/0975-4385.2023.00009
Cite(Electronic):
Sonam Sharma, Nisha Sharma, Prakash Chandra Gupta, Ruchi Verma, Vandana Yadav. An Update on Kidney Stones: Types, Mechanism and Treatment Approaches. Research Journal of Pharmacognosy and Phytochemistry. 2023; 15(1):53-2. doi: 10.52711/0975-4385.2023.00009 Available on: https://rjpponline.org/AbstractView.aspx?PID=2023-15-1-9
REFERENCES:
1. C. O’Callaghan, P. V. Yangkul and L. Ammi Visnaga, Eds., Blackwell Publishing Ltd., Oxford, UK,doi.org/10.1155/2018/3068365 2006
2. K. Mikawlrawng, S. Kumar, and R. Vandana, “Current scenario of urolithiasis and the use of medicinal plants as antiurolithiatic agents in Manipur (North East India): a re-view,” International Journal of Herbal Medicine, vol. 2, no. 1, pp. 1–12, 2014.
3. V. K. Sigurjonsdottir, H. L. Runolfsdottir, O. S. Indridason et al., “Impact of nephrolithiasis on kidney function,” BMC Nephrology, vol. 16, no. 1, p. 149, 2015.
4. Z. M. El-Zoghby, J. C. Lieske, R. N. Foley et al., “Urolithiasis and the risk of ESRD,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 9, pp. 1409–1415, 2012.
5. A. D. Rule, V. L. Roger, L. J. Melton et al., “Kidney stones associate with increased risk for myocardial infarction,” Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1641–1644, 2010.
6. E. M. Worcester and F. L. Coe, “Nephrolithiasis,” Primary Care, vol. 35, no. 2, pp. 369–391, 2008.
7. E. N. Taylor, M. J. Stampfer, and G. C. Curhan, “Obesity, weight gain and the risk of kidney stones,” Journal of the American Medical Association, vol. 293, no. 4, pp. 455–462, 2005.
8. S. B. N. Kumar, K. G. Kumar, V. Srinivasa, and S. Bilal, “A review on urolithiasis,” International Journal of Universal Pharmacy and Life Sciences, vol. 2, no. 2, pp. 269–280, 2012.
9. J. M. Teichman and M. H. Joel, “Acute renal colic from ureteral calculus,” New England Journal of Medicine, vol. 350, no. 7, pp. 684–693, 2004.
10. K. P. Aggarwal, S. Narula, M. Kakkar, and C. Tandon, “Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators,” BioMed Research International, vol. 2013, Article ID 292953, 21 pages, 2013.
11. S. R. Khan, D. J. Kok, “Modulators of urinary stone formation,” Frontiers In Bioscience, vol. 9, no. 1–3, pp. 1450–1482, 2004.
12. O. W. Moe, “Kidney stones: pathophysiology and medical management,” The Lancet, vol. 367, no. 9507, pp. 333–344, 2006.
13. Cappuccio, F.P., Kalaitzidis, R., Duneclift, S., Eastwood, J.B., 2000. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J. Nephrol. 13(3), 169-177
14. Daudon, M., Frochot, V., Bazin, D., Jungers, P., 2018. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs 78(2), 163-201.
15. Chaussy, C., Schmiedt, E., Jocham, B., Brendel, W., Forssmann, B., Walther, V., 1982. First clinical experience with extracorporeally induced destruction of kidney stones by shock waves. J. Urol. 127,417-20.
16. Odvina, C.V., Sakhaee, K., Heller, H. J., Peterson, R.D., Poindexter, J.R., Padalino, P.K., Pak, C.Y., 2007. Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol. Res. 35(3), 123-128
17. D. R. Basavaraj, C. S. Biyani, A. J. Browning, and J. J. Cartledge, “The role of urinary kidney stone inhibitors and promoters in the pathogenesis of calcium containing renal stones,” EAU-EBU Update Series, vol. 5, no. 3, pp. 126–136, 2007.
18. M. S. Parmar, “Kidney stones,” British Medical Journal, vol. 328, no. 7453, pp. 1420–1424, 2004.
19. S. Ahmed, M. M. Hasan, and Z. M. Alam, “In vitro urolithiasis models: an evaluation of prophylactic management against kidney stones,” Journal of Pharmacognosy and Phytochemistry, vol.5, no. 3, pp. 28–35, 2016.
20. E. O. Kajander and N. Ciftcioglu, “Nanobacteria: an alternative mechanism for pathogenic intra-and extracellular calcification and stone formation,” Proceedings of the National Academy of Sciences, vol. 95, pp. 8274–8279, 1998.4, pp. 435–447, 2013.5.2. Crystal Growth
21. H. Xu, A. L. Zisman, F. L. Coe, and E. M. Worcester, “Kidney stones: an update on current pharmacological management and future directions,” Expert Opinion on Pharmacotherapy, vol. 14, no. 4, pp. 435–447, 2013.
22. V. N. Ratkalkar and J. G. Kleinman, “Mechanisms of stone formation,” Clinical Reviews in Bone and Mineral Metabolism, vol. 9, no. 3-4, pp. 187–197, 2011.
23. S. R. Khan, “Renal tubular damage/dysfunction: key to the formation of kidney stones,” Urological Research, vol. 34, no. 2, pp. 86–91, 2006.
24. M. Tsujihata, “Mechanism of calcium oxalate renal stone formation and renal tubular cell injury,” International Journal of Urology, vol. 15, no. 2, pp. 115–120, 2008.
25. C. F. Verkoelen, B. G. vander Boom, and J. C. Romijn, “Identification of hyaluronan as a crystal-binding molecule at the surface of migrating and proliferating MDCK cells,” Kidney Inernational, vol. 58, no. 3, pp. 1045–1054, 2000.
26. J. C. Lieske, H. Swift, T. Martin, B. Patterson, and F. G. Toback, “Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals,” Proceedings of the National Academy of Sciences, vol. 91, no. 15, pp. 6987–6991, 1994.
27. B. Hess, “Tamm-Horsfall glycoprotein-inhibitor or promoter of calcium oxalate monohydrate crystallization processes,” Urological Research, vol. 20, no. 1, pp. 83–86, 1992.
28. L. Mo, H. Y. Huang, X. H. Zhu, E. Shapiro, D. L. Hasty, and X.-R. Wu, “Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation,” Kidney International, vol. 66, no. 3, pp. 1159–1166, 2004.
29. R. Hackett, P. Shevock, and S. Khan, “Madin-Darby canine kidney cells are injured by exposure to oxalate and to calcium oxalate crystals,” Urological Research, vol. 22, no. 4, pp. 197–203, 1994.
30. J. M. Fasano and S. R. Khan, “Intra-tubular crystallization of calcium oxalate in the presence of membrane vesicles: an invitro study,” Kidney International, vol. 59, pp. 169–178, 2001.
31. T. Rashed, M. Menon, and S. Tamilselvan, “Molecular mechanism of oxalate-induced free radical production and glutathione redox imbalance in renal epithelial cells: effect of antioxidants,” American Journal of Nephrology, vol. 24, no. 5, pp. 557–568, 2004.
32. L. S. Chaturvedi, S. Koul, A. Sekhon, A. Bhandari, M. Menon, and H. K. Koul, “Oxalate selectively activates p38 mitogen activated protein kinase and C-Jun N-terminal kinase signal transduction pathways in renal epithelial cells,” Journal of Biological Chemistry, vol. 277, no. 15, pp. 13321–13330, 2002.
33. S. Koul, L. Khandrika, T. J. Pshak et al., “Oxalate upregulates expression of IL-2Rβ and activates IL-2R signaling in HK-2 cells, a line of human renal epithelial cells,” American Journal of Renal Physiology, vol. 306, pp. 1039–1046, 2014.
34. N. Hsieh, C. H. Shih, and H. Y. Chen, “Effects of Tamm- Horsfall protein on the protection of MCDK cells from oxalate induced free radical injury,” Urological Research, vol. 31, pp. 10–16, 2003.
35. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 2005;115:2598-2608.
36. Reid DG, Jackson GJ, Duer MJ, et al. Apatite in kidney stones is a molecular composite with glycosaminoglycans and proteins: evidence from nuclear magnetic resonance spectroscopy, and relevance to Randall’s plaque, pathogenesis and prophylaxis. J Urol. 2011;185:725-730.
37. C. H. Dawson and C. R. V. Tomson, “Kidney stone disease: pathophysiology, investigation and medical treatment,” Journal of Clinical Medicine, vol. 12, no. 5, pp. 467–471, 2012.
38. M. Lopez and B. Hoppe, “History, epidemiology and regional diversities of urolithiasis,” Pediatric Nephrology, vol. 25, no.1, pp. 49–59, 2008.
39. Zacchia, M., Preisig, P., 2010. Low urinary citrate: an overview. J Nephrol. 23(6), S49.
40. O'neill, W.C., Lomashvili, K.A., Malluche, H.H., Faugere, M.C., Riser, B.L., 2011. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney international 79(5), 512- 517.
41. Wang, L., Zhang, W., Qiu, S.R., Zachowicz, W. J., Guan, X., Tang, R., Nancollas, G.H., 2006. Inhibition of calcium oxalate monohydrate crystallization by the combination of citrate and osteopontin. Journal of crystal growth 291(1), 160-165.
42. Atmani, F., Opalko, F.J., Khan, S.R., 1996. Association of urinary macromolecules with calcium oxalate crystals induced in vitro in normal human and rat urine. Urol Res. 24(1), 45-50.
43. V. Centeno, G. D. de Barboza, and A. Marchionatti, “Molecular mechanisms triggered by low-calcium diets,” Nutrition Research Reviews, vol. 22, no. 2, pp. 163–174, 2009. Advances in Urology 11
44. B. Cakıro˘glu, E. Eyyupo˘glu, A. I. Hazar, B. S. Uyanik, and B. Nuho˘glu, “Metabolic assessment of recurrent and first renal calcium oxalate stone formers,” ArchivioItaliano di Urologia e Andrologia, vol. 88, pp. 101–105, 2016.
45. S. R. Marengo and A. M. Romani, “Oxalate in renal stone disease: the terminal metabolite that just won’t go away,” Nature Clinical Practice Nephrology, vol. 4, no. 7, pp. 368–377, 2008
46. Aggarwal, K. P., Narula, S., Kakkar, M., & Tandon, C., 2013. Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators. Bio. Med. Res. Int. 2013, 292953.
47. Evan, A.P., Worcester, E.M., Coe, F.L., Williams, J., Lingeman, J.E., 2015. Mechanisms of human kidney stone formation. Urolithiasis 43(1), 19-32.
48. Corbetta, S., Baccarelli, A., Aroldi, A., Vicentini, L., Fogazzi, G. B., Eller-Vainicher, C., Spada, A., 2005. Risk factors associated to kidney stones in primary hyperparathyroidism. J. Endocrinol. Invest. 28(4), 122-128.
49. N. Chhiber, M. Sharma, T. Kaur, and S. Singla, “Mineralization in health and mechanism of kidney stone formation,” International Journal of Pharmaceutical Science Invention, vol. 3, pp. 25–31, 2014.
50. C. Barbasa, A. Garciaa, L. Saavedraa, and M. Muros, “Urinary analysis of nephrolithiasis markers,” Journal of Chromatography B, vol. 781, no. 1-2, pp. 433–455, 2002.
51. A. Chaudhary, S. K. Singla, and C. Tandon, “In vitro evaluation of Terminalia arjuna on calcium phosphate and calcium oxalate crystallization,” Indian Journal of Pharmaceutical Sciences, vol. 72, no. 3, pp. 340–345, 2010.
52. A. Bensatal and M. R. Ouahrani, “Inhibition of crystallization of calcium oxalate by the extraction of Tamarix gallica L,” Urological Research, vol. 36, no. 6, pp. 283–287, 2008.
53. F. Dal-Moro, M. Mancini, I. M. Tavolini, V. De Marco, and P. Bassi, “Cellular and molecular gateways to urolithiasis: a new insight,” Urologia Internationalis, vol. 74, pp. 193–197, 2005.
54. D. V. Kishore, F. Moosavi, and D. R. K. Varma, “Effect of ethanolic extract of Portulaca oleracea linn. on ethylene glycol and ammonium chloride induced urolithiasis,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 5, no. 2, pp. 134–140, 2013.
55. Nijenhuis T, Hoenderop JG, Loffing J, van der Kemp AW, van Os CH, Bindels RJ. Thiazide-induced hypocalciuria is accompanied by a decreased expression of Ca2+ transport proteins in kidney. Kidney Int 2003;64:555-64.
56. Guirguis-Blake J. Preventing recurrent nephrolithiasis in adults. Am Fam Physician 2014;89:461-3.
57. Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, et al. Medical management of kidney stones: AUA guideline. J Urol2014;192:316-24.
58. Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol2003;169:465-9.
59. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol1993;150:1761-4.
60. Robinson MR, Leitao VA, Haleblian GE, Scales CD Jr, Chandrashekar A, Pierre SA, et al. Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. J Urol2009;181:1145-50.
61. M. Dursun, A. Otunctemur, and E. Ozbek, “Kidney stones and ceftriaxone,” European Medical Journal of Urology, vol. 3, no. 1, pp. 68–74, 2015.
62. L. Giannossi and V. Summa, “A review of pathological biomineral analysis techniques and classification schemes,” in An Introduction to the Study of Mineralogy, C. Aydinalp, Ed., InTechOpen, InTech, IMAA-CNR, Italy, 2012, http://www.intechopen.com/books/.
63. T. C. Ngo and D. G. Assimos, “Uric acid nephrolithiasis: recent progress and future directions,” Reviews in Urology, vol. 9, pp. 17–27, 2007.
64. Fellstrom B, Danielson BG, Karlstrom B, Lithell H, Ljunghall S, Vessby B, et al. Effects of high intake of dietary animal protein on mineral metabolism and urinary supersaturation of calcium oxalate in renal stone formers. Br J Urol1984;56:263-9.
65. Best S, Tracy C, Bagrodia A, Poindexter J, Adams-Huet B, Sakhaee K, et al. Effect of various animal protein sources on urinary stone risk factors [Internet]. Linthicum, MD: American Urological Association; c2014 [cited 2014 Nov 24]. Available from: https://www.auanet.org/university/abstract_detail.cfm?id=2147&meetingID=11WAS.
66. Reiser S, Powell AS, Scholfield DJ, Panda P, Ellwood KC, Canary JJ. Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose corn starch. Am J Clin Nutr1989;49:832-9.
67. K. Ahmed, P. Dasgupta, and M. S. Khan, “Cystine calculi: challenging group of stones,” Postgraduate Medical Journal, vol. 82, no. 974, pp. 799–801, 2006.
68. Sakhaee K, Maalouf NM, Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab2012;97:1847-60.
69. Barbey F, Joly D, Rieu P, Mejean A, Daudon M, Jungers P. Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol2000;163:1419-23.
70. Jaeger P, Portmann L, Saunders A, Rosenberg LE, Thier SO. Anticystinuric effects of glutamine and of dietary sodium restriction. N Engl J Med 1986;315:1120-3.
71. Rodríguez LM, Santos F, Malaga S, Martinez V. Effect of a low sodium diet on urinary elimination of cystine in cystinuric children. Nephron 1995;71:416-8.
72. Rodman JS, Blackburn P, Williams JJ, Brown A, Pospischil MA, Peterson CM. The effect of dietary protein on cystine excretion in patients with cystinuria. Clin Nephrol 1984;22:273-8.
73. Saravakos P, Kokkinou V, Giannatos E. Cystinuria: current diagnosis and management. Urology 2014;83:693-9.
74. D. P. Griffith, “Struvite stones,” Kidney International, vol. 13, no. 5, pp. 372–382, 1978.
75. Williams JJ, Rodman JS, Peterson CM. A randomized double blind study of acetohydroxamic acid in struvite nephrolithiasis. N Engl J Med 1984;311:760-4.
76. Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N. Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. EurUrol1991;20:243-7.
77. Rodman JS, Williams JJ, Jones RL. Hypercoagulability produced by treatment with acetohydroxamic acid. Clin PharmacolTher1987;42:346-50.
78. Saltel E, Angel JB, Futter NG, et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164:1895–1897.
79. Sundaram CP, Saltzman B. Urolithiasis associated with protease inhibitors. J Endourol. 1999;13:309–312.
80. Janbaz, K. H., Saeed, S. A., and Gilani, A. H. (2002). Protective effect of rutin on paracetamol- and CCl4-induced hepatotoxicity in rodents. Fitoterapia, 73(7-8):557-653.
81. Ghodasara, J., Pawar, A., Deshmukh, C., et al. (2011). Inhibitory effect of rutin and curcumin on experimentally-induced calcium oxalate urolithiasis in rats. Pharm Res, 2(6):388-392.
82. Cabrera, C., Artacho, R., and Giménez, R. (2006). Beneficial Effects of Green Tea—A Review. J Am Coll Nutr, 25(2):79-99.
83. Zhai, W., Zheng, J., Yao, X., et al. (2013). Catechin prevents the calcium oxalate monohydrate induced renal calcium crystallization in NRK-52E cells and the ethylene glycol induced renal stone formation in rat. BmcComplem Altern M, 13(1):228.
84. Grases, F., Prieto, R. I., Sanchis, P., et al. (2009). Phytotherapy and renal stones: the role of antioxidants: A pilot study in Wistar rats. Urolithiasis, 37(1):35-40.
85. Barberán, F. A. T., Gil, M. I., Tomás, F., et al. (1985). Flavonoid Aglycones and Glycosides from Teucrium gnaphalodes. J Nat Prod, 48(5):859-860.
86. Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT, et al. Medical therapy to facilitate urinary stone passage: A meta-analysis. Lancet. 2006;368:1171–9.
87. Granados Loarca EA. Medical treatment of uric acid lithiasis of the urinary tract and usefulness of double J catheter. Arch Esp Urol. 2001;54:157–61
88. Phatak R S and HendreA S 2015 In-vitro antiurolithiatic activity of Kalanchoe pinnata extract,” Int. J. Pharmacogn. Phytochem. Res. 7 275–279
89. Shashi Alok, Sanjay Kumar Jain, Amita Verma, Mayank Kumar, Monika Sabharwal. Pathophysiology of kidney, gallbladder and urinary stones treatment with herbal and allopathic medicine: A review. Asian Pac J Trop Dis 2013; 3(6): 496-504.
90. Bawari S, Negi Sah A and Tewari D 2018 Antiurolithiatic activity of Daucus carota: an in vitro study Pharmacogn. J. 10 880–884
91. Saha S and Verma R J 2013 Inhibition of calcium oxalate crystallisation in-vitro by an extract of Bergenia ciliata Arab J. Urol. 11 187–192